Patents by Inventor Karin Lovgren-Bengtsson

Karin Lovgren-Bengtsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240024468
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: October 4, 2023
    Publication date: January 25, 2024
    Applicant: Novavax AB
    Inventors: Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
  • Publication number: 20220241408
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: August 4, 2022
    Inventors: Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
  • Publication number: 20200345840
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: December 3, 2019
    Publication date: November 5, 2020
    Applicant: Novavax AB
    Inventors: Bror MOREIN, Karin LÖVGREN BENGTSSON, Jill EKSTRÖM, Katarina RANLUND, Kefei HU
  • Patent number: 10813994
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: October 27, 2020
    Assignee: Novavax AB
    Inventors: Bror Morein, Karin Lovgren-Bengtsson
  • Publication number: 20200323979
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Application
    Filed: January 22, 2018
    Publication date: October 15, 2020
    Inventors: Bror MOREIN, Karin LOVGREN-BENGTSSON
  • Patent number: 10736958
    Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: August 11, 2020
    Assignee: Novavax AB
    Inventors: Albertus D. M. E. Osterhaus, Bror Morein, Karin Lovgren Bengtsson
  • Patent number: 10729764
    Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja Saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: August 4, 2020
    Assignee: Novavax AB
    Inventors: Bror Morein, Karin Lövgren Bengtsson
  • Publication number: 20200215189
    Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.
    Type: Application
    Filed: March 19, 2020
    Publication date: July 9, 2020
    Inventors: Bror MOREIN, Karin LÖVGREN-BENGTSSON
  • Publication number: 20190388534
    Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or lore influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
    Type: Application
    Filed: January 29, 2019
    Publication date: December 26, 2019
    Inventors: Albertus D.M.E. OSTERHAUS, Bror MOREIN, Karin LOVGREN BENGTSSON
  • Patent number: 10485863
    Abstract: The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: November 26, 2019
    Assignees: Novavax AB, Erasmus University Rotterdam Medical Center
    Inventors: Albertus D. M. E. Osterhaus, Bror Morein, Karin Lövgren Bengtsson
  • Publication number: 20180369369
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 27, 2018
    Inventors: Bror MOREIN, Karin LOVGREN-BENGTSSON
  • Publication number: 20180369368
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: January 18, 2018
    Publication date: December 27, 2018
    Applicant: NOVAVAX AB
    Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
  • Patent number: 9901634
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 27, 2018
    Assignee: NOVAVAX AB
    Inventors: Bror Morein, Karin Lovgren Bengtsson
  • Publication number: 20160184427
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 30, 2016
    Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
  • Publication number: 20160114034
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Application
    Filed: November 5, 2015
    Publication date: April 28, 2016
    Inventors: Bror MOREIN, Karin Lovgren BENGTSSON
  • Patent number: 9205147
    Abstract: Iscom particles can be used as an adjuvant for preparing of an antigenic composition which comprises live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A composition may comprise at least one iscom particle and one or more live micro-organisms and/or killed micro-organisms and/or antigenic molecules. A kit can comprise at least one compartment containing at least one living organism and at least one compartment containing at least one iscom particle.
    Type: Grant
    Filed: January 2, 2014
    Date of Patent: December 8, 2015
    Assignee: Novavax AB
    Inventors: Bror Morein, Karin Lövgren Bengtsson
  • Publication number: 20150320858
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: May 18, 2015
    Publication date: November 12, 2015
    Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
  • Publication number: 20150209425
    Abstract: The invention relates to a composition comprising a mixture of at least two iscom complexes each complex comprising essentially one saponin fraction from Quillaja Saponaria Molina. The complexes may be iscom complexes or iscom matrix complexes. The invention also pertains to the use of such a mixture for the preparation of an immunomodulating pharmaceutical, and adjuvant, formulations for immunization, e.g. for production of monoclonal antibodies, and a vaccine. Kits of parts comprising at least two parts, wherein each part comprises one iscom complex or one iscom matrix complex according to the invention are also embraced.
    Type: Application
    Filed: December 31, 2014
    Publication date: July 30, 2015
    Inventors: BROR MOREIN, KARIN LÖVGREN BENGTSSON
  • Publication number: 20140335049
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
  • Patent number: 8821881
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, blockpolymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A. CpG variants, CT and LT or fractions thereof.
    Type: Grant
    Filed: July 7, 2004
    Date of Patent: September 2, 2014
    Assignee: Novavax AB
    Inventors: Bror Morein, Karin Lovgren Bengtsson, Jill Ekstrom, Katarina Ranlund, Kefei Hu